European regulatory authorities gave Teva a positive opinion for its DuoResp Spiromax inhalation powder, designed to treat asthma and chronic obstructive pulmonary disease. With the recommendation from the Committee for Medicinal Products for Human Use, Teva hopes to have final approval within a few months.
3M licensed its dry powder drug delivery device for asthma and chronic obstructive pulmonary disease to Adamis for an undisclosed amount, granting the smaller company worldwide rights to bolster its own line of delivery devices.
Australian scientists have found a new way to develop ultrafine particles that make inhalable drug delivery more consistent and efficient for the treatment of lung conditions such as asthma.
Prosonix says its new platform for multi-API powders could be the way to boost effectiveness for inhaled treatments.
Forest Laboratories ($FRX) says it will use Germany to launch the European Union rollout of Colobreathe, its new dry powder inhalation treatment for cystic fibrosis-related lung infections, by...
Adding a new long-term inhaled dry powder version of mannitol to standard therapy helps improve lung function in cystic fibrosis patients for up to a year, according to a new study. But the forced